Palmitoyl-KTSKS (Palmitoyl Pentapeptide-4) is a synthetic lipo-peptide developed by Sederma with selective antimicrobial (not bacteriocide) activity and known under the trade name BB-Biont™. Intriguing, it shares an INCI name with one of the most well-known Sederma peptides, Matrixyl (Palmitoyl-KTTKS). The sequence KTSKS (Lys-Thr-Ser-Lys-Ser) is found in the human Laminin protein subunit α-1 (2228-2233), so it can be considered a matrikine.
Screening of different peptides that can suppress the growth of Cutibacterium acnes (Propionibacterium acnes), Palmitoyl-KTTKS, showed promising results and exhibits other advantages, such as modulating the release of pro-inflammatory cytokines, stimulating fibroblasts, and promoting the production of extracellular matrix components.
By decreasing bacterial cell adhesion, Palmitoyl-KTSKS interferes with quorum sensing, thereby reducing biofilm production and virulence. In addition, it reduces bacterial lipases, enzymes that are responsible for hair follicle inflammation and skin irritation. Moreover, Pal-KTSKS decreases the release of IL-6 and increases the release of IL-1Ra, limiting inflammation.
Thanks to Matrixyl-like (matrikine) action, Palmitoyl-KTSKS increases the production of hyaluronic acid, collagen-I, collagen-IV, and fibronectin. It enhances skin hydration, increases corneal layer thickness, reinforces barrier function, and accelerates acne-induced scar healing.Clinical trials showed a decrease in skin redness, roughness, and blemishes. It improves skin surface relief, prevents acne scar formation, and restores healthy appearance.
